Recently, Medtronic announced that its infused bone graft stent has received approval from the Australian Therapeutic Goods Administration (TGA). This regulatory clearance allows the company to officially market and sell the infused bone graft stent, known as LT-CAGE, across Australia. The device is designed for use in spinal fusion procedures and serves as an internal fixation system that supports the spine during the healing process.
The infused bone graft stent/LT-CAGE is specifically developed to treat degenerative disc disease. It consists of two main components: a small, hollow, threaded metal cone and a bone graft bracket. When implanted, the LT-CAGE helps restore the natural height of the degenerated disc, alleviating pressure on the surrounding nerves. This restoration can effectively reduce symptoms caused by nerve compression, such as pain, numbness, and tingling in the lower back and legs.
By combining structural support with biological integration, the LT-CAGE promotes long-term spinal stability and enhances patient recovery. This innovation marks a significant advancement in the treatment of lumbar spine conditions, offering a more effective and durable solution for patients suffering from chronic back pain due to disc degeneration. With this new approval, healthcare providers in Australia now have access to a cutting-edge option for improving patient outcomes in spinal surgery.
CAS NO 56353-15-2 N-ACETYL-CARNOSINE,CAS NO 24587-37-9 VAL-TRP，PHE-PHE used in pharmaceutical industry,PHE-PHE CAS NO 2577-40-4
Ronas Chemicals Ind. Co.,Ltd. , https://www.ronaschemical-cn.com